# Cardioprotective effect of resveratrol in myocardial ischemia/reperfusion injury and myocardial infarction: a pre-clinical meta-analysis in animal studies

## TL;DR

This study finds that resveratrol may protect the heart in animal models of heart injury, but more research is needed to confirm its effectiveness in humans.

## Contribution

A pre-clinical meta-analysis showing resveratrol reduces heart damage in animal models of ischemia/reperfusion injury and myocardial infarction.

## Key findings

- Resveratrol treatment decreased myocardial infarct size in MIRI and MI animal models.
- Resveratrol improved cardiac function and reduced oxidative stress and inflammation in heart injury models.
- The study highlights the need for standardized protocols and clinical trials to confirm resveratrol's cardioprotective effects.

## Abstract

This meta-analysis aimed to assess the cardioprotective effect of resveratrol (RES) against myocardial ischemia/reperfusion injury (MIRI) and myocardial infarction (MI) in the animal. PubMed, Web of Science, and EMBASE were searched. Primary outcomes included myocardial infarct size (IS) and cardiac function. Secondary outcomes included cardiac injury enzyme, oxidative stress level, inflammatory cytokine, and apoptosis rate. Subgroup analysis, publication bias, sensitivity analysis, meta-regression, and dosage-efficacy analysis were used to evaluate the risk of bias. Fifty-seven studies were included involving 1,125 animals. The results showed that RES treatment decreased IS in animal models of MIRI (SMD: −5.44; 95% CI [−6.42 to −4.45]; P < 0.01; I2 = 86%) and MI (SMD: −3.41; 95% CI [−4.44 to −2.38]; P < 0.01; I2 = 75%). Moreover, RES treatment improved cardiac function, decreased cardiac injury enzymes, down-regulated oxidative stress levels, alleviated inflammatory cytokine levels, and reduced apoptosis rate in animal models of MIRI and MI. This meta-analysis of preclinical animal studies suggested that RES may have potential in alleviating MIRI and MI. However, the translational potential of RES remains uncertain, and additional preclinical studies with standardized protocols, comorbid models, and eventual clinical trials are needed to confirm these results.